581 results about "Ferroptosis" patented technology

The invention discloses a tumor cholesterol metabolism regulation microneedle patch and a preparation method, the microneedle patch comprises a needle tip and a backing which are connected, the needle tip comprises a needle tip body and nanoparticles loaded on the needle tip body, the nanoparticle is a manganese ion-doped organic metal framework, the outer layer of the manganese ion-doped organic metal framework is modified with a targeting agent, cholesterol oxidase and superoxide dismutase are carried on the manganese ion-doped organic metal framework, the targeting agent can target a CD44 receptor, and the organic metal framework can carry drugs. The targeted drug can enter tumor cells in a targeted mode, superoxide dismutase catalyzes superoxide anions overexpressed in the tumor cells to generate H2O2 and O2, O2 needed by catalysis is provided for cholesterol oxidase, cholesterol at the tumor site is consumed by the cholesterol oxidase, accumulation of 7-DHC is reduced, meanwhile H2O2 can be generated, and the cholesterol oxidase can be used for catalyzing the tumor site. H2O2 is catalyzed by manganese ions through a Fenton-like reaction to generate OH to induce tumor cells to generate ferroptosis, so that ferroptosis-immune synergistic treatment is realized.

According to the GPX4 protein degradation agent and the application, the degradation agent serves as molecular glue to induce tumor cell ferroptosis and is different from an existing PROTAC technology, and the molecular glue can induce interaction between E3 ubiquitin ligase and target protein GPX4 and promote ubiquitination of the E3 ubiquitin ligase and the target protein GPX4. Compared with the existing GPX4 degradation agent, the molecular glue has the advantages of small molecular weight, high cell permeability and better druggability. The GPX4 molecular glue disclosed by the invention can be used for effectively degrading GPX4 and has a killing effect on various tumor cell lines. The preparation method is simple in synthesis route and mild in reaction condition, can be used for being developed into a new generation of GPX4 targeting drugs, and has great clinical application value and considerable market potential.

The invention relates to the technical field of biological medicine, in particular to a ferroptosis inhibition type phospholipid-like material and application thereof. The ferroptosis inhibition type phospholipid-like material is one of the following structural general formulas (1)-(5). The biomimetic phospholipid-like ferroptosis inhibitor has a long retention characteristic in main positions (cell membranes, endoplasmic reticulum and other organelle membranes) of cell ferroptosis, so that the ferroptosis inhibition efficiency is remarkably improved. The novel phospholipid-like material not only can be used as an active drug molecule, but also can be used as a pharmaceutic adjuvant for constructing drug delivery carriers such as lipidosome and micelle and implant coatings, and is suitable for various administration routes such as oral administration, injection and local administration. The novel biomimetic ferroptosis inhibitor can efficiently relieve cell ferroptosis and has a wide application prospect in the field of treating or retarding ferroptosis-related diseases.

The invention relates to a training method of a respiratory tract infection disease progress and prognosis prediction model. The training method comprises the following steps: extracting mRNA from peripheral blood of a target patient, and carrying out transcriptome sequencing to obtain a sequencing result; based on the ferroptosis related gene set, comparing ferroptosis score differences of two groups of patients with community-acquired pneumonia and sepsis, and screening corresponding ferroptosis related genes with statistical significance from a sequencing result; screening out genes meeting preset conditions from the ferroptosis related genes based on LASSO regression; and establishing an RTI clinical outcome prediction model through logistic regression by taking whether the patient is sepsis or not as an outcome dichotomy variable and taking the screened gene expression quantity as a prediction variable. According to the invention, after the prediction model is subjected to machine learning screening such as LASSO and the like, the core feature with the highest prediction value is reserved, so that the risk of over-fitting of the model on training data is reduced.

The invention relates to an STING gene knockout TIL capable of enhancing anti-tumor activity and a preparation method and application of the TIL, in particular to a genetically engineered immune cell, and an STING gene in the genetically engineered immune cell is silenced or down-regulated. The ferroptosis resistance of the immune cell provided by the invention is remarkably enhanced, the immune cell can be better infiltrated into a tumor microenvironment, and the immune cell has a remarkable anti-tumor effect.

The invention provides application of a small molecule drug for promoting triple negative breast cancer ferroptosis, and belongs to the technical field of tumor treatment. The inducer can effectively kill triple negative breast cancer cells by triggering a ferroptosis pathway. The invention discovers that the inhibitor can reduce the expression of a key protein RPTOR by inhibiting the activity of an mTORCl compound, thereby weakening the anti-oxidation defense capability of triple negative breast cancer cells, greatly enhancing the accumulation of lipid peroxide, and further strongly inducing the occurrence of ferroptosis. The component of the culture medium is a DMEM (Dulbecco Modified Eagle Medium) containing 10% of fetal calf serum, and 2 [mu] M of Torinl is added at the same time. The invention discloses a new target spot of ferroptosis of the triple-negative breast cancer, and provides a new thought for treatment of the triple-negative breast cancer.

The invention relates to a structure, synthesis and application of morpholine ring oligonucleotide. A morpholine ring oligonucleotide structure is named Mo-CEBPA, can induce intracellular redox imbalance and trigger ferroptosis by inhibiting expression of CEBPA in hepatoma carcinoma cells, can assist sorafenib in killing hepatoma carcinoma cells, and overcomes the defect that existing drugs cannot efficiently induce hepatoma carcinoma cell ferroptosis.

The invention belongs to the technical field of medical nano-materials, and particularly relates to a preparation method of a nano-metal covalent organic framework material for enhancing cell ferroptosis by consuming glutathione as well as an obtained product and application of the nano-metal covalent organic framework material. The material is prepared by the following steps: firstly, preparing a metal organic ligand Cu3-PyCA3; the preparation method comprises the following steps: firstly, preparing a metal organic ligand Cu3-PyCA3, then mixing the metal organic ligand Cu3-PyCA3, 2, 5-diethoxybenzene-1, 4-bis (formylhydrazine), mesitylene, 1, 4-dioxane and a trifluoroacetic acid solution, and then reacting to obtain a nano metal covalent organic framework Cu3-MCOF; and finally, uniformly mixing the activated hyaluronic acid solution and the Cu3-MCOF, and intensely stirring to obtain the Cu3-MCOF-coated HA. The nano-metal covalent organic framework provided by the invention can consume glutathione to enhance cell ferroptosis, and the nano-metal covalent organic framework Cu3-MCOF can quickly react with glutathione, so that the framework structure of the Cu3-MCOF is seriously damaged, the crystalline state disappears, a large number of ribbons are further assembled and generated, glutathione is consumed, and the ferroptosis of cells is enhanced. The ferroptosis tumor treatment enhancer has an application prospect.

The invention discloses a solid lipid nanoparticle-inulin gel compound for targeted therapy of ulcerative colitis and a preparation method of the solid lipid nanoparticle-inulin gel compound, and belongs to the technical field of medicines, the compound comprises inulin gel and solid lipid nanoparticles dispersed in the inulin gel; the solid lipid nanoparticle comprises a glyceride shell, oleic acid coated by the glyceride shell, a medicine with anti-inflammatory and anti-oxidation effects, and cationic lipid, the mass ratio of the oleic acid to the medicine with the anti-inflammatory and anti-oxidation effects to the cationic lipid is 1: (1-1.5): (2.5-3); the drug loading capacity in the solid lipid nanoparticles is 1 to 10 weight percent. According to the compound, the inulin gel serves as a delivery system, functional solid lipid nanoparticles are carried in the compound, intestinal ferroptosis can be reduced, active oxygen can be removed, the compound has the effects of promoting intestinal barrier repair, relieving inflammatory response and the like, and the compound has good application prospects in the aspect of treatment of ulcerative colitis.

The invention relates to the technical field of biological medicine, in particular to 7-dehydrocholesterol liposome and application thereof. According to the invention, a biological membrane modified liposome is constructed, and the biological membrane modified liposome comprises an ROS responsive liposome, a neutrophile granulocyte membrane and a renal tubular epithelial cell membrane; the biofilm modified liposome has an active oxygen species (ROS) responsive release function and a dual targeting capability, has the advantages of an integrated drug effect carrier, ROS triggered release, dual bionic targeting, strong target cell uptake and multi-mechanism ferroptosis resistance, and can be used for preparing the biofilm modified liposome. The compound can be used for treating ferroptosis related diseases such as acute kidney injury, myocardial ischemia-reperfusion injury and cerebral ischemia-reperfusion injury, and has wide clinical popularization value.

The application belongs to the technical field of antitumor drugs, and discloses an iron complex as well as a preparation method and application thereof.The preparation steps of the iron complex are as follows: 1, reacting 2-hydrazinylbenzothiazole, a ketone compound and a solvent to obtain a ligand; and 2, reacting the ligand, ferric chloride and a solvent, and then cooling and crystallizing to obtain the iron complex.The obtained iron complex can effectively induce cancer cell ferroptosis, can effectively inhibit the growth of breast cancer, lung cancer, liver cancer or glioma, has high selectivity, has small toxicity to normal cell strains, and has better treatment effect compared with existing clinical drugs, such as cisplatin.

The application discloses a sensitized ferroptosis lipid nano regulator and a preparation method and application thereof, and belongs to the technical field of new adjuvants and new dosage forms of drug preparation combined treatment. The lipid nano regulator is co-assembled by a GPX4 inhibitor and a FASN inhibitor through intermolecular forces, and is modified with an oxidation-reduction sensitive PEG modifier, a molar ratio of the GPX4 inhibitor and the FASN inhibitor is 10:1-1:10, a mass ratio of the sum of the GPX4 inhibitor and the FASN inhibitor to the PEG modifier is 10:90-90:10, and the intermolecular forces include pi-pi stacking force, hydrophobic force and hydrogen bond. The co-assembled nano preparation provides a new strategy and more choices for the development of drug delivery, and meets the urgent needs of high-efficiency and diverse ferroptosis treatment strategies in preparations in the clinic.

The invention discloses a magnetic-aptamer targeting tumor tissue nano-drug delivery system as well as a preparation method and application thereof, and belongs to the field of medicines. The system comprises a mesoporous ferroferric oxide magnetic core, a polyethyleneimine (PEI) layer coated outside the mesoporous ferroferric oxide magnetic core and an aptamer adsorbed outside the PEI layer, and an autophagy activator can be selectively loaded in the mesoporous core. The preparation method comprises the following steps: sequentially carrying out drug loading, PEI coating and aptamer modification on the mesoporous Fe3O4 nanoparticles. According to the invention, efficient enrichment and endocytosis of tumor tissues are realized through dual effects of magnetic targeting and active targeting of the aptamer; lysosome escape is promoted by using the proton sponge effect of PEI; finally, by virtue of the synergistic effect of iron ions released by degradation of the Fe3O4 nanoparticles and endogenous iron ions released by ferritin autophagy induced by an autophagy activator, ferroptosis of tumor cells is induced through enhanced Fenton-like reaction, so that high-efficiency and low-toxicity targeted therapy is realized.

This invention discloses a multi-target synergistic anti-liver cancer medical food granule and its preparation method. The granule uses medicinal and edible homologous foods and novel resource foods as raw materials, and is composed of curcumin extract, esterified fat-soluble EGCG, Moringa leaf powder, yeast β-glucan, Astragalus extract, Schisandra extract, Salvia miltiorrhiza extract, Poria cocos powder, resistant dextrin, and erythritol in a specific ratio to construct a three-dimensional synergistic system of "direct killing-immune regulation-liver protection," which can induce ferroptosis in liver cancer cells, inhibit protective autophagy, activate the body's immunity, and protect liver cells. This invention employs directional extraction, multi-layer coating, and high-pressure fusion granulation technology. Nanoparticle liposome encapsulation, esterification modification, and pH-responsive enteric coating improve the stability and bioavailability of the components, solving the problems of poor water solubility, low absorption, and easy degradation of natural active ingredients. The granule has clear efficacy, high safety, and stable process, and can be used as a medical food for adjuvant therapy and nutritional support during the recovery period of liver cancer.

The invention belongs to the field of biosensing and fluorescence imaging, and particularly relates to a fluorescent probe compound and application thereof. The probe compound is a compound as shown in a formula I or a compound as shown in a formula II, or a pharmaceutically acceptable salt thereof; the structures of the compound in the formula I and the compound in the formula II are shown in the specification, and the definition of each group is shown in any embodiment of the invention. The fluorescent probe compound shows rapid and high reactivity to oxidizing free radicals, the generated fluorescent compound is high in fluorescence intensity and good in stability, and early diagnosis can be carried out on ferroptosis-related disease models such as oxygen-glucose deprivation / reperfusion and drug liver injury on living cell or living body levels and the like. I II

The invention relates to the technical field of anti-cancer chemical drugs, in particular to a thiadiazole tetranuclear copper complex with anti-tumor and antibacterial activity and a preparation method and application of the thiadiazole tetranuclear copper complex. The chemical formula of the complex is [Cu4 (C3H3S2N2) 2 (C3H4S2N2) 4], the complex is synthesized from ligand thiadiazole and CuX, X is I or Br, and copper in the obtained complex is + 1 valence. The complex shows a good cytotoxic effect on breast cancer cells MCF-7, is likely to play a toxic effect by inducing apoptosis, ferroptosis, copper death and other ways, has a good antibacterial effect, has potential medicinal value, and is expected to be developed into a new generation of anti-tumor drugs with antibacterial properties.

The application discloses a new use of Leonurine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating radiation-induced brain injury, specifically, providing a safe and effective therapeutic drug for iron death, neuroinflammation, neuron damage and lipid metabolism disorder accompanying the radiation-induced brain injury, solving the technical problem of lack of specific treatment means in the prior art, and having a wide clinical application prospect. Experiments adopt a C57BL / c mouse 30 Gy whole brain X-ray radiation model, and results show that Leonurine can significantly improve the body weight decrease and survival rate of the model mice, reduce the serum IL-6 and IFN-alpha levels, inhibit the activation of microglial cells in the cerebral cortex and hippocampus, protect and repair damaged neurons, and improve the ultrastructure of mitochondria and synapses; meanwhile, the expression of GPX4 and SLC7A11 proteins in the brain tissue is up-regulated, the GSH content is increased to inhibit iron death, and the levels of GPE, GPS and GPC related to lipid metabolism are restored.

This invention discloses a method for constructing a prognostic model for acute myeloid leukemia (AML) based on ferroptosis-related genes. The method involves acquiring gene expression data from AML patients and healthy samples to screen for differentially expressed ferroptosis-related genes (DEGs) associated with AML. Using univariate Cox proportional hazards regression analysis, LASSO regression analysis, and multivariate Cox proportional hazards regression analysis, key genes ACSF2, SLC7A11, DNAJB6, and SOCS1 are selected from these DEGs. A prognostic risk model is constructed based on the expression levels of these key genes and their corresponding multivariate Cox regression coefficients. The risk score formula is: Risk Score = 0.534 × ACSF2 expression value - 0.453 × DNAJB6 expression value + 0.194 × SLC7A11 expression value + 0.308 × SOCS1 expression value. The prognostic model constructed in this invention has high predictive accuracy and reliability, effectively stratifying the risk and assessing the prognosis of AML patients, providing an important reference for the clinical treatment of AML.

The invention belongs to the technical field of biology, and particularly relates to application of baicalin to preparation of a medicine for treating preeclampsia by inhibiting trophoblast ferroptosis induced by NETs. The baicalin inhibits downstream signal transduction by specifically interfering a key activation step of PKC [beta] 2 and a membrane translocation process coupled with a second signal, and finally plays a role in inhibiting ferroptosis of trophoblasts. The discovery provides a brand new perspective for understanding the molecular action mechanism of the medicine. According to the application, baicalin influences ferroptosis induced by NETs in trophoblast cells by inhibiting membrane translocation and activation of PKC beta2, so that the biological function of baicalin is exerted. The discovery of the mechanism further deepens the important significance of people on NETs and baicalin in disease induction and treatment, and a thought is provided for research and development of a new treatment scheme for preeclampsia.

The invention discloses an application of ametinib in preparation of a medicine for treating liver cancer, belongs to the technical field of new application of medicines, and verifies the potential of third generation EGFR-TKI ametinib in inhibiting liver cancer progression in vivo and in vitro, and cell function experiments prove that ametinib can effectively inhibit proliferation, migration and invasion ability of liver cancer cells; the exact type of ametinib for inducing liver cancer cell death is determined, and ametinib inhibits survival and proliferation of liver cancer cells by activating autophagy and inducing ferroptosis; the application proves that autophagy activated by the ametinib can promote the occurrence of ferroptosis by regulating and controlling the degradation of GPX4 (glutathione peroxidase 4) and the accumulation of reactive oxygen species (ROS), and the ametinib inhibits the progress of liver cancer by inducing autophagy-dependent ferroptosis, so that the ametinib is used for preparing the medicine for treating liver cancer.

The invention discloses an application of samidocardone in preparation of a medicine for treating pulmonary fibrosis. According to the application disclosed by the invention, the condition that the samidojun can inhibit the activity of the pulmonary fibrosis cells and reduce proliferation by inducing the ferroptosis of the pulmonary fibrosis cells is proposed and verified for the first time, and meanwhile, the expression of fibrosis-related proteins is reduced, so that the progress of the pulmonary fibrosis is effectively relieved, and a new direction is provided for treating the pulmonary fibrosis.

Disclosed are 1,2,4,5-tetraoxane compounds and derivatives thereof having anticancer properties. Disclosed are pharmaceutical compositions and pharmaceutical formulations in unit dosage form suitable for delivering the compounds to a subject in need thereof. In addition to the compounds, the pharmaceutical compositions or formulations can include one or more active agents, such as one or more additional anticancer agents. Also disclosed are methods of treating, mitigating, or treating or ameliorating one or more symptoms associated with cancer in a subject. The methods include (i) administering to a subject in need thereof an effective amount of a compound. The compound can be administered by oral administration, parenteral administration, inhalation, mucosal administration, or a combination thereof. The compound can selectively kill cancer cells and / or cancer stem cells, but not non-cancer cells, by inducing ferroptosis in the cancer cells and / or cancer stem cells.

The present invention relates to a medium composition for in vitro fertilization and / or in vitro culture comprising a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof, and a method using same. The compound or composition suppresses reactive oxygen species and lipid peroxidation in ovarian granulosa cells to preventing cytotoxicity and mitochondrial dysfunction caused by apoptosis and ferroptosis, leading to an improvement in the quality of aged oocytes, and to increase the developmental rate and blastocyst formation rate of pre-implantation embryos, thereby improving the efficiency of in vitro fertilization. In addition, treatment with the medium composition during the vitrification process of in vitro–fertilized embryos improves re-expansion and survival rates, thereby reducing structural and metabolic damage. Accordingly, the present invention can be advantageously applied to an assisted reproductive technology for treating infertility and subfertility, and in vitro fertilization and / or in vitro culture for improving the propagation efficiency of livestock.

The invention belongs to the technical field of medicine preparation, and particularly relates to application of DHGC in preparation of a medicine for treating acute kidney injury ferroptosis mediated by an SIRT3 / NRF2 axis. Experiments prove that DHGC can activate SIRT3 in a targeted manner, up-regulate the expression level of SIRT3, promote NRF2 deacetylation and drive NRF2 nuclear translocation, and further up-regulate the expression level of GPX4, so that the effect of resisting ferroptosis caused by acute kidney injury is achieved.

The invention provides a cancer subtype classification method, system, equipment and program product based on ferroptosis related miRNA, and belongs to the field of intelligent medical treatment. The breast cancer is divided into four subtypes on the basis of ferroptosis related miRNA, the breast cancer FAP + subtype is identified on the basis of ferroptosis activity, the molecular characteristics of the FAP + subtype of an individual breast cancer patient are measured by establishing FAPscore, and the higher the FAPscore is, the more remarkable the FAP + subtype characteristics of the breast cancer patient are. The invention also finds that FAPscore can be used for predicting response, prognosis and drug sensitivity of individual cancer patients to immunotherapy response, and the discovery has wide cross-cancer species applicability and is not limited to breast cancer. The invention provides a new insight for a more effective and individualized treatment strategy of cancer.

This invention discloses a ferroptosis target identification system and method based on an attention mechanism, belonging to the field of artificial intelligence technology. The system includes modules for extracting multi-source features of ferroptosis regulation, labeling weak signal targets, calculating attention potential energy mapping, and ranking ferroptosis targets. It extracts multimodal features from transcriptome expression, molecular interaction networks, and ferroptosis pathway annotations. Targets with expression intensities below a preset threshold that participate in the ferroptosis pathway are labeled with weak signals. Weak signal characteristics are injected, and a potential energy bias is constructed to complete attention potential energy mapping. Then, through pathway mapping and cross-pathway linkage identification and fusion weights, the target linkage degree is calculated and ranked. This system solves the problem of traditional methods easily neglecting weak signal targets, and can identify targets with insignificant expression changes in the ferroptosis regulatory network. Through attention and pathway-level linkage modeling, the comprehensiveness of target identification is improved, and the obtained ranking results have stability and discriminative power, making it suitable for the identification and research of ferroptosis-related targets.

The application belongs to the technical field of biological pharmacy, and provides metabolites for MAFLD based on multi-omics joint analysis and application thereof, wherein the metabolites include metabolites of Bacteroides uniformis bacteria for preparing a drug for treating MAFLD, the metabolites of Bacteroides uniformis bacteria are hexadecanedioic acid, and the application is an application of HDA in preparation of a drug for treating and / or relieving MAFLD. The application verifies a regulation effect of XBP1 as a key target molecule of HDA intervention on lipid metabolism disorder and ferroptosis in the MAFLD course, and verifies a relief effect of HDA on MAFLD in mice, thereby providing a theoretical basis and practical guidance for development of a new type of MAFLD treatment drug, and having important clinical significance.

The invention discloses a dual-channel fluorescent probe for simultaneously detecting nitric oxide and cysteine as well as a preparation method and application of the dual-channel fluorescent probe. The structural formula of the dual-channel fluorescent probe is shown in the specification. The invention also specifically discloses a preparation method of the dual-channel fluorescent probe and application of the dual-channel fluorescent probe in selective detection of NO and Cys, dynamic visual detection of NO and Cys in a biological cell system and in ferroptosis and depression cell models. The dual-channel fluorescent probe disclosed by the invention has the advantages of strong specificity, good selectivity, no spectrum crosstalk and the like.

The application provides an application of intracellular peroxide combined glutamine deprivation in an ACSL4-independent tumor cell metastasis inhibiting drug sensitive to ferroptosis. The technical problem in the prior art that ferroptosis tolerance is more conducive to tumor cell metastasis is solved, and a new intervention strategy for effectively inhibiting tumor cell metastasis with low ferroptosis sensitivity is developed.

The invention discloses application of a nerve injury induction protein 1 in preparation of a gastric cancer diagnosis and treatment product. The invention finds that the overexpression of NINJ1 not only can enhance the sensitivity of gastric cancer cells to ferroptosis by down-regulating the expression of aldehyde ketoreductase AKR1C1 / 2 / 3, but also can up-regulate the expression of MHC-I molecules on the surfaces of tumor cells, promote the presentation of tumor antigens and increase the infiltration of CD8 + T cells, so that the dual anti-tumor function is exerted; therefore, NINJ1 overexpression and an immune checkpoint inhibitor (such as a PD-L1 antibody) or a ferroptosis inducer are combined for use, so that the immunotherapy effect can be synergistically improved. The invention provides a brand new targeting strategy for overcoming the immune drug resistance of gastric cancer and improving the treatment effect, and has important clinical transformation value.